Glenmark’s Remogliflozin Hopes To Shake Up Indian SGLT2i Market

Glenmark’s remogliflozin is priced about 50% lower than the other SGLT2 inhibitors in India and is expected to expand access to the class of drugs significantly. Early physician outlook for the new SGLT2 inhibitor appears encouraging.

Diabetes
GLENMARK HAS LAUNCHED A NOVEL SGLT2 Inhibitor

Glenmark Pharmaceuticals Ltd.’s teneligliptin effectively changed market dynamics in the Indian gliptins segment in 2015 when it made a debut at a price that was 55% lower than the other DPP4 inhibitors at the time – teneligliptin volumes have since surged, overshadowing peers in the class. And the Mumbai-based company now appears to be hoping for a similar run with another diabetes therapy, remogliflozin etabonate, that has hit the Indian market backed by an aggressive cut-price approach.

[Sidebar#SC099667]

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from India

More from Focus On Asia